Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $227.5 million.

  • RxSight's Cash & Equivalents fell 404.89% to $227.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.5 million, marking a year-over-year decrease of 404.89%. This contributed to the annual value of $237.2 million for FY2024, which is 8647.8% up from last year.
  • According to the latest figures from Q3 2025, RxSight's Cash & Equivalents is $227.5 million, which was down 404.89% from $227.5 million recorded in Q2 2025.
  • RxSight's 5-year Cash & Equivalents high stood at $237.2 million for Q4 2024, and its period low was $61.7 million during Q2 2021.
  • Its 5-year average for Cash & Equivalents is $164.3 million, with a median of $150.5 million in 2023.
  • Per our database at Business Quant, RxSight's Cash & Equivalents surged by 13846.23% in 2021 and then crashed by 3358.44% in 2022.
  • Over the past 5 years, RxSight's Cash & Equivalents (Quarter) stood at $159.3 million in 2021, then tumbled by 33.58% to $105.8 million in 2022, then increased by 20.23% to $127.2 million in 2023, then surged by 86.48% to $237.2 million in 2024, then fell by 4.09% to $227.5 million in 2025.
  • Its last three reported values are $227.5 million in Q3 2025, $227.5 million for Q2 2025, and $229.3 million during Q1 2025.